Brain health specialist Neural Analytics, Inc., has raised $15 million to develop its Lucid System to assess and monitor additional brain health conditions
The Lucid Transcranial Doppler Ultrasound System (Lucid System) uses ultrasound to assess the brain’s blood vessels from outside the body. This analysis is non-invasive, can be performed in the physician’s office, and helps the physician diagnose brain disorders. The system is FDA-cleared and CE-marked for the monitoring of blood flow velocities in the cerebral vasculature. The Lucid System is a battery-operated, medical-grade tablet device designed to be transported easily throughout a medical facility and in a range of clinical scenarios that require the rapid assessment of blood flow in the brain to expedite treatment.
Recently presented data has demonstrated that the company’s Lucid System is capable of measuring and displaying large vessel occlusion (LVO) with 91 percent sensitivity and 85 percent specificity as compared to the current standard of care imaging in persons suspected of having a stroke.
“This round of funding will allow us to build on the momentum we have generated in 2017 and expand our team as we further advance the development of the Lucid System to assess and monitor additional brain health conditions,” said Leo Petrossian, Ph.D., Co-Founder and Chief Executive Officer of Neural Analytics, Inc.
Source: Neural Analytics, Inc